

Date: September 27, 2023

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited (“Company”) dated September 27, 2023, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

Dear Sir/Madam,

This is in reference to our intimation on the outcome of the meeting of the Board of Directors of the Company (“**Board**”) dated February 8, 2023 and Committee of Directors (Rights Issue) dated July 27, 2023 for approval of issue of equity shares by way of a rights issue for an amount not exceeding ₹1,050 crore (“**Rights Issue**”) and for approving the various terms of the Rights Issue respectively. Further, the meeting of Committee of Directors (Rights Issue) dated August 22, 2023 approved the allotment of 12,96,04,598 Equity Shares which excluded 25,032 shares pertaining to persons that are subject to legal proceedings and were accordingly, kept in abeyance.

In relation to the aforesaid Rights Issue, the Committee of Directors (Rights Issue) at its meeting held today, i.e., September 27, 2023, *inter alia*, considered and approved the allotment of 25,032 Equity Shares at a price of ₹81 per Equity Share (including a premium of ₹71 per Equity Share) (“**Allotment**”) to the notified persons that are subject to legal proceedings and were accordingly, kept in abeyance.

Accordingly, pursuant to the Allotment, the paid-up equity share capital of the Company has increased from ₹1322,92,30,980 to ₹1322,94,81,300.

This intimation is issued in terms of Regulation 30 of the SEBI Listing Regulations.

You are requested to kindly take note of the same.

For Piramal Pharma Limited

Tanya Sanish
Company Secretary